<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02205164</url>
  </required_header>
  <id_info>
    <org_study_id>AS/PALO/002</org_study_id>
    <secondary_id>2011-003823-36</secondary_id>
    <nct_id>NCT02205164</nct_id>
  </id_info>
  <brief_title>Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients</brief_title>
  <official_title>Phase II Randomized Study of Multiple Doses of Palonosetron Plus Aprepitant Versus Multiple Doses of Palonosetron Alone in Preventing CINV in Patients With Newly Diagnosed AML or High-risk MDS Receiving Multiple Days Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associazione Salentina Angela Serra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Associazione Salentina Angela Serra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of present study is to evaluate if the addition of Aprepitant to multiple doses of
      palonosetron IV enhances the efficacy of multiple doses of palonosetron IV alone, in
      preventing CINV in AML or High risk MDS patient, treated with multiple days chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, comparative, multicenter phase II study in patients with
      AML scheduled to receive multiple days chemotherapy.

      Patients will receive either PALO+APR or the PALO regimen in a 1:1 ratio according to a
      computer-generated, random allocation schedule. Below are described the details for both
      antiemetic regimens:

      PALO+APR regimen: oral aprepitant will be given on days 1-3 (day 1, 125 mg, days 2-3, 80 mg 1
      hour before chemotherapy ) and multiple intravenous bolus of Palonosetron without
      dexamethasone, prior to the administration of chemotherapy, starting the first day of
      treatment.

      PALO regimen: multiple intravenous bolus of Palonosetron without dexamethasone, prior to the
      administration of chemotherapy, starting the first day of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>5 days after chemotherapy</time_frame>
    <description>The primary endpoint is the overall rate of patients achieving a complete response (defined as no emetic episode and no use of rescue medication) during the overall phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Control</measure>
    <time_frame>5 days after chemotherapy</time_frame>
    <description>No emetic episode, no need for rescue medication, with a maximum grade of mild nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emesis-free</measure>
    <time_frame>5 days after chemotherapy</time_frame>
    <description>Percentage of patients without emetic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of nausea</measure>
    <time_frame>5 days after chemotherapy</time_frame>
    <description>Presence of nausea graded according to Likert scale (none, mild, moderate and severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>5 days after chemotherapy</time_frame>
    <description>Time (days) to treatment failure (first emetic episode or first need of rescue medication, whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global satisfaction</measure>
    <time_frame>5 days after chemotherapy</time_frame>
    <description>Patient global satisfaction with antiemetic therapy, as measured by a visual analogue scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>5 days after chemotherapy</time_frame>
    <description>Number of patients experienced at least one adverse events related to study drug administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Chemotherapy Induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Palonosetron + Aprepitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral aprepitant will be given on days 1-3 (day 1, 125 mg 1 h before chemohterapy; days 2-3, 80 mg) multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palonosetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron + Aprepitant</intervention_name>
    <description>Aloxi 0.25mg Emend 125/80/80 mg</description>
    <arm_group_label>Palonosetron + Aprepitant</arm_group_label>
    <other_name>Aloxi + Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>Aloxi 0.25mg</description>
    <arm_group_label>Palonosetron</arm_group_label>
    <other_name>Aloxi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Acute Myeloid Leukaemia or High-risk MDS according to IPSS

          -  Patient eligible for AML-like induction therapy

          -  Candidate for multiple-days chemotherapy (minimum 3 days)

          -  Age more, equal18 years

          -  ECOG 0-2

          -  Not pregnant or nursing

          -  Must be able to complete the patient's diary

          -  Provide written informed consent

        Exclusion Criteria:

          -  AML or HR-MDS therapy-related

          -  Active infection requiring intravenous antibiotics

          -  Prior malignancies at other sites except surgically treated non-melanoma skin cancer,
             prostate cancer, superficial cervical cancer, or other cancer from which the patient
             had been disease-free for more/equal 5 years

          -  Unacceptable hepatic function (more of 2 times the upper limit of normal for liver
             transaminases) and renal function (creatinine more of 1.5 times the upper limit of
             normal) unless disease-related

          -  Myocardial infarction within the past 6 months

          -  Psychiatric or CNS disorders interfering with ability to comply with study protocol

          -  Known hypersensitivity to 5-HT3 antagonists and their components CSF involvement

          -  Pre-existing nausea or vomiting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Di Renzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Vito Fazzi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicola Di Renzo, MD</last_name>
    <email>direnzo.ematolecce@libero.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Quintavalle, BsC</last_name>
    <email>quinta.ematolecce@libero.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universit√†-Azienda Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Perrino</name>
      <address>
        <city>Brindisi</city>
        <state>BR</state>
        <zip>72010</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Melpignano, MD</last_name>
      <email>brinemat@tin.it</email>
    </contact>
    <investigator>
      <last_name>Angela Melpignano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pugliese-Ciacco</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>FG</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla, MD</last_name>
      <email>nicola.cascavilla@tin.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <state>LE</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo, MD</last_name>
      <email>direnzo.ematolecce@libero.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Cardinale Panico&quot;</name>
      <address>
        <city>Tricase</city>
        <state>LE</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Pavore, MD</last_name>
      <email>salentoematologia@piafondazionepanico.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Pavone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Riuniti Papardo - Piemonte</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donato Mannina, MD</last_name>
      <email>donadani@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Donato Mannina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa di Cura &quot;La Maddalena&quot;</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Musso, MD</last_name>
      <email>mamusso@libero.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Musso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Ascoli Civico Palermo</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anxur Merenda, MD</last_name>
      <email>anxurmerenda@libero.it</email>
    </contact>
    <investigator>
      <last_name>Anxur Merenda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Moscati</name>
      <address>
        <city>Taranto</city>
        <state>TA</state>
        <zip>74100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizio Mazza, MD</last_name>
      <email>ematologia.taranto@libero.it</email>
    </contact>
    <investigator>
      <last_name>Patrizio Mazza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ARON &quot; Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <zip>80121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicetto Ferrara, MD</last_name>
      <email>felicettoferrara@katamail.com</email>
    </contact>
    <investigator>
      <last_name>Felicetto Ferrara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2014</study_first_posted>
  <last_update_submitted>July 30, 2014</last_update_submitted>
  <last_update_submitted_qc>July 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>palonosetron</keyword>
  <keyword>aprepitant</keyword>
  <keyword>CINV</keyword>
  <keyword>AML</keyword>
  <keyword>multiple-days</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

